Shukla A, Sharma A, Gupta S, Mishra A, Singh A. Antitumor potential of ivermectin against T-cell lymphoma-bearing hosts. Med Oncol. 2025;42:169. https://doi.org/10.1007/s12032-025-02726-0.

Article  PubMed  CAS  Google Scholar 

Sharma A, Raut SS, Dhikale P, Khusboo, A Mishra Navigating the landscape of cancer-induced thrombocytopenia: current challenges and emerging advances. In: Verma P (ed) Industrial microbiology and biotechnology. Singapore: Springer Nature Singapore; 2024. pp. 435-63.

Sharma A, Raut SS, Shukla A, Gupta S, Singh A, Mishra A. DDX3X dynamics, glioblastoma’s genetic landscape, therapeutic advances, and autophagic interplay. Med Oncol. 2024;41:258. https://doi.org/10.1007/s12032-024-02525-z.

Article  PubMed  Google Scholar 

Sharma A, Raut SS, Shukla A, Gupta S, Mishra A, Singh A. From tissue architecture to clinical insights: spatial transcriptomics in solid tumor studies. Semin Oncol. 2025;52:152389. https://doi.org/10.1016/j.seminoncol.2025.152389.

Article  PubMed  CAS  Google Scholar 

Ray PP, Islam MA, Islam MS, Han A, Geng P, Aziz MA, et al. A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment. Front Pharm. 2024;15:1349745 https://doi.org/10.3389/fphar.2024.1349745.

Article  CAS  Google Scholar 

Zare Mehrjerdi P, Asadi S, Ehsani E, Askari VR, Baradaran Rahimi V. Silibinin as a major component of milk thistle seed provides promising influences against diabetes and its complications: a systematic review. Naunyn-Schmiedeberg’s Arch Pharm. 2024;397:7531–49. https://doi.org/10.1007/s00210-024-03172-x.

Article  CAS  Google Scholar 

Selc M, Macova R, Babelova A. Novel strategies enhancing bioavailability and therapeutical potential of silibinin for treatment of liver disorders. Drug Des Dev Ther. 2024;18:4629–59. https://doi.org/10.2147/DDDT.S483140.

Article  Google Scholar 

Wang Y, Yang W, Yang Y, Liu X, Peng L, Huang Q, et al. Evidence construction of Silibinin capsules against alcoholic liver disease based on a meta-analysis and systematic review. Front Pharm. 2025;16:1516204.

Article  CAS  Google Scholar 

Ball KR, Kowdley KV. A review of Silybum marianum (milk thistle) as a treatment for alcoholic liver disease. J Clin Gastroenterol. 2005;39:520–8.

Article  PubMed  Google Scholar 

Choi YH. Silibinin alleviates DNA damage, mitochondrial dysfunction, and apoptosis caused by oxidative stress in human retinal pigment epithelial cells. Mol Cell Toxicol. 2024;20:709–21.

Article  CAS  Google Scholar 

Vahabi A, Öztürk AM, Kılıçlı B, Birim D, Kaftan Öcal G, Dağcı T, et al. Silibinin promotes healing in spinal cord injury through anti-ferroptotic mechanisms. JOR Spine. 2024;7:e1344.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mishra SD, Mendonca P, Kaur S, Soliman KF. Silibinin anticancer effects through the modulation of the tumor immune microenvironment in triple-negative breast cancer. Int J Mol Sci. 2025;26:6265.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Romanucci V, Pagano R, Kandhari K, Zarrelli A, Petrone M, Agarwal C, et al. 7-O-tyrosyl silybin derivatives as a novel set of anti-prostate cancer compounds. Antioxidants. 2024;13:418.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Fu J, Liu W, Liu S, Zhao R, Hayashi T, Zhao H, et al. Inhibition of YAP/TAZ pathway contributes to the cytotoxicity of silibinin in MCF-7 and MDA-MB-231 human breast cancer cells. Cell Signal. 2024;119:111186.

Article  PubMed  CAS  Google Scholar 

Hossein-Tehrani M, Abbasalipourkabir R, Ziamajidi N. The role of miR-133a in silibinin-mediated inhibition of the PI3K/AKT/mTOR pathway in MCF-7 breast carcinoma cells. Mol Biol Res Commun. 2024;13:79.

PubMed  PubMed Central  Google Scholar 

Wang X. The effects of silibinin combined with EGFR-TKIs in the treatment of NSCLC. Cancer Med. 2025;14:e70643.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lotia S, Patel S, Patel A, Patel V, Shah K, Tanavde V. Unravelling the role of Silibinin in targeting CD44+ cancer stem cells: therapeutic implications, effective strategies and approaches. Phytother Res. 2024;38:1830–7.

Article  PubMed  CAS  Google Scholar 

You Y, He Q, Lu H, Zhou X, Chen L, Liu H, et al. Silibinin induces G2/M cell cycle arrest by activating Drp1-dependent mitochondrial fission in cervical cancer. Front Pharm. 2020;11:271.

Article  CAS  Google Scholar 

Mannelli LDC, Zanardelli M, Failli P, Ghelardini C. Oxaliplatin-induced neuropathy: oxidative stress as pathological mechanism. Protective effect of silibinin. J Pain. 2012;13:276–84.

Article  Google Scholar 

Singh N, Ali M, Biswal P, Jaiswal A, Mishra D, Agarwal R, et al. Inhibition of growth and survival of head and neck cancer cells by silibinin involves the down-regulation of Erk1/2, AKT and STAT3 signaling. Mol Carcinog. 2025. https://doi.org/10.1002/mc.70022.

Article  PubMed  Google Scholar 

Xiao B, Jiang Y, Yuan S, Cai L, Xu T, Jia L. Silibinin, a potential fasting mimetic, inhibits hepatocellular carcinoma by triggering extrinsic apoptosis. MedComm. 2024;5:e457.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mardani-Nafchi H, Heidari-Soureshjani S, Rostamian S. A systematic review of silymarin and silibinin mechanisms for attenuating cerebral ischemia-reperfusion injuries. Avicenna J Phytomed. 2025;15:1279.

PubMed  PubMed Central  Google Scholar 

Dehghan A, Ghanbarzadeh S, Ghiass M, Imani M. Silibinin solubilization: combined effect of co-solvency and inclusion complex formation. Drug Dev Ind Pharm. 2024;50:470–80.

Article  PubMed  CAS  Google Scholar 

Xie Y, Zhang D, Zhang J, Yuan J. Metabolism, transport and drug–drug interactions of silymarin. Molecules. 2019;24:3693.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tang N, Wu D, Lu Y, Chen J, Zhang B, Wu W. A comparative study on the stability of silybin and that in silymarin in buffers and biological fluids. Drug Metab Lett. 2009;3:115–9.

Article  PubMed  CAS  Google Scholar 

Li L, Zeng J, Gao Y, He D. Targeting silibinin in the antiproliferative pathway. Expert Opin Investig Drugs. 2010;19:243–55.

Article  PubMed  CAS  Google Scholar 

Molavi O, Narimani F, Asiaee F, Sharifi S, Tarhriz V, Shayanfar A, et al. Silibinin sensitizes chemo-resistant breast cancer cells to chemotherapy. Pharm Biol. 2017;55:729–39.

Article  PubMed  CAS  Google Scholar 

Sadava D, Kane SE. Silibinin reverses drug resistance in human small-cell lung carcinoma cells. Cancer Lett. 2013;339:102–6.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sharma A, Kumar S, Pahil V. Anticancer therapeutic potential of silibinin: current trends, scope and relevance. Med Chem Res. 2025;34:809–24.

Lim R, Morwood CJ, Barker G, Lappas M. Effect of silibinin in reducing inflammatory pathways in in vitro and in vivo models of infection-induced preterm birth. PLoS ONE. 2014;9:e92505.

Article  PubMed  PubMed Central  Google Scholar 

Kaipa JM, Starkuviene V, Erfle H, Eils R, Gladilin E. Transcriptome profiling reveals Silibinin dose-dependent response network in non-small lung cancer cells. PeerJ. 2020;8:e10373.

Article  PubMed  PubMed Central  Google Scholar 

Wing Ying Cheung C, Gibbons N, Wayne Johnson D, Lawrence Nicol D. Silibinin-a promising new treatment for cancer. Anti-Cancer Agents Med Chem. 2010;10:186–95.

Article  Google Scholar 

Wu W, Wang Y, Que L. Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. Eur J Pharm Biopharm. 2006;63:288–94. https://doi.org/10.1016/j.ejpb.2005.12.005.

Article  PubMed  CAS